Nicole Pommery and Jean-Pierre Henichart Pages 1125 - 1132 ( 8 )
This review presents some therapeutic interventions actually considered in prostate cancer therapy to compensate constitutive activation of the PI3K/Akt signalling pathway induced, particularly, by mutations of PTEN gene. Special emphasis is placed on applicability of EGF-R tyrosine kinase, COX-2, PDK-1, mTOR and farnesyltransferase inhibitors.
Prostate cancer, PI3K/Akt/mTOR pathway, growth inhibition
Institut de Chimie Pharmaceutique Albert Lespagnol, Université de Lille 2, Lille, France.